Performance History
| Key Stats | |
|---|---|
| Open | $2.21 |
| Prev. Close | $2.19 |
| EPS | -11.14 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | 7843370.00 |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 2.04 | 2.27 |
| 52 Week Range | 0.18 | 48.79 |
| Ratios | |
|---|---|
| P/B Ratio | 18.94 |
| Revenue | - |
| Operating M. % | -127.25% |
| Earnings | $0.00 |
| Earnings Growth % | 43.04% |
| EBITDA Margin % | -120.82% |
| ROEÂ % | -521.22% |
| EPS | -11.14 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 66 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| VVOS | MARKET | |
|---|---|---|
| Value | 47 | 38 |
| Quality | 36 | 40 |
| Ownership | 8 | 17 |
| Growth | 90 | 46 |
| Dividends | - | 37 |
Vivos Therapeutics's Price discount from 1 year high of 94.22% is great compared to market average of 16.77%. This indicates VVOS could be a good value stock.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Vivos Therapeutics (VVOS)
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. R. Kirk Huntsman
- Headquarters
- Littleton
- Employees
- 154
- Exchange
- NASDAQ
Keep an eye on Vivos Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Vivos Therapeutics's (VVOS) price per share?
The current price per share for Vivos Therapeutics (VVOS) is $2.12. The stock has seen a price change of -$0.06 recently, indicating a -2.97% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Vivos Therapeutics (VVOS)?
For Vivos Therapeutics (VVOS), the 52-week high is $48.79, which is 2.2K% from the current price. The 52-week low is $0.18, the current price is 1.08K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Vivos Therapeutics (VVOS) a growth stock?
Vivos Therapeutics (VVOS) has shown an average price growth of 0.41% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vivos Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Vivos Therapeutics (VVOS) stock price performance year to date (YTD)?
As of the latest data, Vivos Therapeutics (VVOS) has a year-to-date price change of -81.99%. Over the past month, the stock has experienced a price change of -22.45%. Over the last three months, the change has been -58.66%. Over the past six months, the figure is -37.5%.
Is Vivos Therapeutics (VVOS) a profitable company?
Vivos Therapeutics (VVOS) has a net income of -$13.58M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 55.43% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -127.25% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $7.65M. Operating income is noted at -$17.3M. Furthermore, the EBITDA is -$16.68M.
What is the market capitalization of Vivos Therapeutics (VVOS)?
Vivos Therapeutics (VVOS) has a market capitalization of $7.84M. The average daily trading volume is 59.36K, indicating the stock's liquidity and investor engagement.
News
Xiaomi and Samsung Smartphones Identified Among Top Radiation Emitters in 2024
Traders Pile Up Short Positions as Grayscale Abandons Ethereum Futures ETF Plan
Global Smartphone Shipments Jump by 20 Million Units Year-over-Year in Q1 2024
Pixel 8a Unveiled: Google’s AI Revolution Goes Mainstream
Visa’s Quarterly Revenue Jumped by $800 Million YoY and Hit an All-Time High of $8.75 Billion
Samsung Overtakes Apple in Q1 2024 Mobile Phone Shipments with 20.8% Market Share
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.